KYNB KYNTRA BIO, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 921299 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY104.5%
TTM net income YoY-108.0%
TTM EPS YoY-108.0%
Revenue 3-yr CAGR-67.5%
Net income 3-yr CAGR—
Margins
Gross margin5.6%
Operating margin-1,089.4%
Net margin-326.0%
FCF margin-913.7%
EBITDA margin-1,089.4%
Returns
ROE—
ROA-18.6%
ROIC (approx.)—
Asset turnover0.06x
Leverage & solvency
Liabilities / assets114.7%
Debt / equity—
Current ratio1.16x
Interest coverage-6.53x
Cash quality & payout
Operating cash flow / net income2.80x
Accruals ratio33.5%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.76M | -$1.47M | $3.74M | $1.28M | $1.08M | $1.35M | $2.74M | -$123.26M |
| Cost of revenue | $619,000 | $2,000 | $4.11M | $278,000 | -$58,000 | $85,000 | $252,000 | -$20.67M |
| Gross profit | $1.14M | -$1.48M | -$368,000 | $999,000 | $1.13M | $1.26M | $2.49M | -$102.59M |
| R&D expense | $8.27M | $6.82M | $7.57M | $7.27M | $1.21M | $5.87M | $9.18M | $1.49M |
| SG&A expense | $5.76M | $9.27M | $5.86M | $7.25M | $5.29M | $7.06M | $8.11M | -$13.32M |
| Operating income | -$12.87M | -$17.57M | -$13.82M | -$13.51M | -$5.41M | -$12.05M | -$14.92M | -$91.66M |
| Interest expense | $1.63M | $2.37M | $2.43M | $2.41M | $2.08M | $2.01M | $2.26M | -$6.53M |
| Pretax income | $157,000 | $11.97M | -$15.13M | -$14.61M | -$13.15M | -$13.78M | -$16.76M | -$8.66M |
| Income tax | $0 | -$1,000 | $0 | $0 | $0 | -$92,000 | $2,000 | -$52,000 |
| Net income | $157,000 | $11.97M | -$15.20M | -$14.22M | $200.64M | -$7.60M | $4.64M | $17.98M |
| EBITDA | -$12.87M | -$17.57M | -$13.82M | -$13.51M | -$5.23M | -$11.84M | -$14.60M | -$91.31M |
| EPS (basic) | 0.04 | 2.96 | -3.76 | — | 49.61 | -1.88 | 1.15 | — |
| EPS (diluted) | 0.04 | 2.96 | -3.76 | — | 49.61 | -1.88 | 1.15 | — |
| Weighted avg. shares (diluted) | 4.05M | 4.05M | 4.05M | — | 4.04M | 4.04M | 4.04M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $9.90M | $50.64M | $37.00M | $47.87M | $117.97M | $23.37M | $33.61M | $50.48M |
| Short-term investments | $30.39M | $40.67M | $50.24M | $41.11M | — | — | — | $0 |
| Receivables | $3.85M | $347,000 | $5.04M | $216,000 | $121,000 | $136,000 | $147,000 | $481,000 |
| Inventory | $3.25M | $3.38M | $3.38M | $3.74M | $3.86M | $3.86M | $3.15M | $3.15M |
| Current assets | $48.62M | $96.83M | $101.36M | $99.07M | $133.42M | $162.32M | $148.53M | $196.51M |
| PP&E, net | — | — | — | — | — | — | — | $0 |
| Total assets | $48.85M | $101.08M | $109.63M | $119.59M | $137.01M | $178.06M | $165.21M | $214.53M |
| Current liabilities | $41.76M | $36.04M | $28.11M | $29.24M | $35.97M | $155.90M | $73.39M | $133.31M |
| Total liabilities | $56.04M | $109.22M | $118.92M | $115.12M | $119.53M | $359.08M | $340.14M | $398.16M |
| Shareholders' equity | -$29.19M | -$30.14M | -$43.80M | -$30.04M | -$17.03M | -$223.00M | -$216.90M | -$225.60M |
| Shares outstanding | 4.05M | 4.05M | 4.05M | 4.05M | 4.04M | 4.04M | 101.04M | 4.04M |
| Cash flow statement | ||||||||
| Operating cash flow | -$12.24M | -$3.99M | -$13.89M | -$18.33M | -$1.85M | $12.68M | $2.72M | -$30.47M |
| Capital expenditure | $0 | $0 | $0 | $0 | $9,000 | $13,000 | $16,000 | $141,000 |
| Free cash flow | -$12.24M | -$3.99M | -$13.89M | -$18.33M | -$1.86M | $12.67M | $2.70M | -$30.61M |
| Investing cash flow | $14.30M | $17.67M | $3.02M | -$51.71M | $87.16M | -$13,000 | -$16,000 | $1.72M |
| Financing cash flow | -$42.80M | -$5,000 | -$7,000 | -$14,000 | -$85.92M | -$9,000 | -$88,000 | $5,000 |
| Depreciation & amortization | $0 | $0 | $0 | $0 | $183,000 | $212,000 | $318,000 | $342,000 |
| Stock-based compensation | $1.01M | $984,000 | $1.15M | $1.19M | $662,000 | $1.87M | $2.85M | $178,000 |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.